Will MiFID II lead to the rise of the lone analyst?

LONDON (Reuters) – Bruno Bulic doesn’t have any problems asking a question when Swiss biotech firm Basilea Pharmaceutica hosts its earnings call. He’s the only sell-side analyst to cover the company, according to Thomson Reuters data.

Source link

Leave a Reply